Comparison of the Characteristics of Patients With Immunocompromising Conditions With Life-Threatening (≥7 Days of Invasive Mechanical Ventilation, Receipt of Extracorporeal Membrane Oxygenation Support, or Death) Versus Non–Life-Threatening COVID-19
| Patients With Immunocompromising Conditions and Acute COVID-19 . | Life-Threatening Illness (n = 17) . | Non–Life-Threatening Illness (n = 88) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 16.9 (15.8, 18.8) | 14.8 (6.8, 17.5) | .03 |
| Male sex, n (%) | 10 (58.8%) | 50 (56.8%) | 1.00 |
| Race and ethnicity, n (%) | |||
| White, non-Hispanic | 4 (23.5%) | 31 (35.2%) | .21 |
| Black, non-Hispanic | 5 (29.4%) | 16 (18.2%) | |
| Hispanic or Latino | 4 (23.5%) | 31 (35.2%) | |
| Asian | 2 (11.8%) | 5 (5.7%) | |
| Mixed/other race, non-Hispanic | 0 (0%) | 3 (3.4%) | |
| Unknown | 2 (11.8%) | 2 (2.3%) | |
| Type of immunocompromising disorder, n (%) | |||
| Hematologic malignancy | 5 (29.4%) | 28 (31.8%) | 1.00 |
| Solid tumor | 4 (23.5%) | 12 (13.6%) | .29 |
| Primary immunodeficiency and other disorders of hematopoietic cells | 4 (23.5%) | 20 (22.7%) | 1.00 |
| Autoimmune disorders | 3 (17.6%) | 10 (11.4%) | .44 |
| Nonmalignant organ failure with history of solid-organ transplant | 1 (5.9%) | 18 (20.5%) | .30 |
| Immunomodulatory therapies, n (%) | |||
| On chemo/immunosuppressive medication at the time of infection | 11 (64.7%) | 53 (60.2%) | .79 |
| History of HSCT <100 d | 2 (11.8%) | 1 (1.1%) | .07 |
| History of HSCT ≥100 d | 3 (17.6%) | 9 (10.2%) | .41 |
| Clinical characteristics | |||
| Any viral coinfection | 2 (17.6%) | 8 (9.1%) | .66 |
| Any bacterial coinfectiona | 5 (29.4%) | 5 (5.7%) | .009 |
| Any respiratory support | 17 (100.0%) | 58 (65.9%) | .003 |
| Any cardiovascular involvement | 13 (76.5%) | 22 (25.0%) | <.001 |
| Receipt of vasoactive infusions | 13 (76.5%) | 11 (12.5%) | <.001 |
| Any neurologic involvement | 6 (35.3%) | 9 (10.2%) | .02 |
| Any hematologic involvement | 15 (88.2%) | 59 (67.0%) | .09 |
| Any gastrointestinal involvement | 11 (64.7%) | 54 (61.4%) | 1.00 |
| Patients With Immunocompromising Conditions and Acute COVID-19 . | Life-Threatening Illness (n = 17) . | Non–Life-Threatening Illness (n = 88) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 16.9 (15.8, 18.8) | 14.8 (6.8, 17.5) | .03 |
| Male sex, n (%) | 10 (58.8%) | 50 (56.8%) | 1.00 |
| Race and ethnicity, n (%) | |||
| White, non-Hispanic | 4 (23.5%) | 31 (35.2%) | .21 |
| Black, non-Hispanic | 5 (29.4%) | 16 (18.2%) | |
| Hispanic or Latino | 4 (23.5%) | 31 (35.2%) | |
| Asian | 2 (11.8%) | 5 (5.7%) | |
| Mixed/other race, non-Hispanic | 0 (0%) | 3 (3.4%) | |
| Unknown | 2 (11.8%) | 2 (2.3%) | |
| Type of immunocompromising disorder, n (%) | |||
| Hematologic malignancy | 5 (29.4%) | 28 (31.8%) | 1.00 |
| Solid tumor | 4 (23.5%) | 12 (13.6%) | .29 |
| Primary immunodeficiency and other disorders of hematopoietic cells | 4 (23.5%) | 20 (22.7%) | 1.00 |
| Autoimmune disorders | 3 (17.6%) | 10 (11.4%) | .44 |
| Nonmalignant organ failure with history of solid-organ transplant | 1 (5.9%) | 18 (20.5%) | .30 |
| Immunomodulatory therapies, n (%) | |||
| On chemo/immunosuppressive medication at the time of infection | 11 (64.7%) | 53 (60.2%) | .79 |
| History of HSCT <100 d | 2 (11.8%) | 1 (1.1%) | .07 |
| History of HSCT ≥100 d | 3 (17.6%) | 9 (10.2%) | .41 |
| Clinical characteristics | |||
| Any viral coinfection | 2 (17.6%) | 8 (9.1%) | .66 |
| Any bacterial coinfectiona | 5 (29.4%) | 5 (5.7%) | .009 |
| Any respiratory support | 17 (100.0%) | 58 (65.9%) | .003 |
| Any cardiovascular involvement | 13 (76.5%) | 22 (25.0%) | <.001 |
| Receipt of vasoactive infusions | 13 (76.5%) | 11 (12.5%) | <.001 |
| Any neurologic involvement | 6 (35.3%) | 9 (10.2%) | .02 |
| Any hematologic involvement | 15 (88.2%) | 59 (67.0%) | .09 |
| Any gastrointestinal involvement | 11 (64.7%) | 54 (61.4%) | 1.00 |
Abbreviations: COVID-19, coronavirus disease 2019; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range.
aPatients with a positive bacterial culture from any site within 72 hours of admission that was then adjudicated by study staff.
Comparison of the Characteristics of Patients With Immunocompromising Conditions With Life-Threatening (≥7 Days of Invasive Mechanical Ventilation, Receipt of Extracorporeal Membrane Oxygenation Support, or Death) Versus Non–Life-Threatening COVID-19
| Patients With Immunocompromising Conditions and Acute COVID-19 . | Life-Threatening Illness (n = 17) . | Non–Life-Threatening Illness (n = 88) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 16.9 (15.8, 18.8) | 14.8 (6.8, 17.5) | .03 |
| Male sex, n (%) | 10 (58.8%) | 50 (56.8%) | 1.00 |
| Race and ethnicity, n (%) | |||
| White, non-Hispanic | 4 (23.5%) | 31 (35.2%) | .21 |
| Black, non-Hispanic | 5 (29.4%) | 16 (18.2%) | |
| Hispanic or Latino | 4 (23.5%) | 31 (35.2%) | |
| Asian | 2 (11.8%) | 5 (5.7%) | |
| Mixed/other race, non-Hispanic | 0 (0%) | 3 (3.4%) | |
| Unknown | 2 (11.8%) | 2 (2.3%) | |
| Type of immunocompromising disorder, n (%) | |||
| Hematologic malignancy | 5 (29.4%) | 28 (31.8%) | 1.00 |
| Solid tumor | 4 (23.5%) | 12 (13.6%) | .29 |
| Primary immunodeficiency and other disorders of hematopoietic cells | 4 (23.5%) | 20 (22.7%) | 1.00 |
| Autoimmune disorders | 3 (17.6%) | 10 (11.4%) | .44 |
| Nonmalignant organ failure with history of solid-organ transplant | 1 (5.9%) | 18 (20.5%) | .30 |
| Immunomodulatory therapies, n (%) | |||
| On chemo/immunosuppressive medication at the time of infection | 11 (64.7%) | 53 (60.2%) | .79 |
| History of HSCT <100 d | 2 (11.8%) | 1 (1.1%) | .07 |
| History of HSCT ≥100 d | 3 (17.6%) | 9 (10.2%) | .41 |
| Clinical characteristics | |||
| Any viral coinfection | 2 (17.6%) | 8 (9.1%) | .66 |
| Any bacterial coinfectiona | 5 (29.4%) | 5 (5.7%) | .009 |
| Any respiratory support | 17 (100.0%) | 58 (65.9%) | .003 |
| Any cardiovascular involvement | 13 (76.5%) | 22 (25.0%) | <.001 |
| Receipt of vasoactive infusions | 13 (76.5%) | 11 (12.5%) | <.001 |
| Any neurologic involvement | 6 (35.3%) | 9 (10.2%) | .02 |
| Any hematologic involvement | 15 (88.2%) | 59 (67.0%) | .09 |
| Any gastrointestinal involvement | 11 (64.7%) | 54 (61.4%) | 1.00 |
| Patients With Immunocompromising Conditions and Acute COVID-19 . | Life-Threatening Illness (n = 17) . | Non–Life-Threatening Illness (n = 88) . | P . |
|---|---|---|---|
| Age, median (IQR), y | 16.9 (15.8, 18.8) | 14.8 (6.8, 17.5) | .03 |
| Male sex, n (%) | 10 (58.8%) | 50 (56.8%) | 1.00 |
| Race and ethnicity, n (%) | |||
| White, non-Hispanic | 4 (23.5%) | 31 (35.2%) | .21 |
| Black, non-Hispanic | 5 (29.4%) | 16 (18.2%) | |
| Hispanic or Latino | 4 (23.5%) | 31 (35.2%) | |
| Asian | 2 (11.8%) | 5 (5.7%) | |
| Mixed/other race, non-Hispanic | 0 (0%) | 3 (3.4%) | |
| Unknown | 2 (11.8%) | 2 (2.3%) | |
| Type of immunocompromising disorder, n (%) | |||
| Hematologic malignancy | 5 (29.4%) | 28 (31.8%) | 1.00 |
| Solid tumor | 4 (23.5%) | 12 (13.6%) | .29 |
| Primary immunodeficiency and other disorders of hematopoietic cells | 4 (23.5%) | 20 (22.7%) | 1.00 |
| Autoimmune disorders | 3 (17.6%) | 10 (11.4%) | .44 |
| Nonmalignant organ failure with history of solid-organ transplant | 1 (5.9%) | 18 (20.5%) | .30 |
| Immunomodulatory therapies, n (%) | |||
| On chemo/immunosuppressive medication at the time of infection | 11 (64.7%) | 53 (60.2%) | .79 |
| History of HSCT <100 d | 2 (11.8%) | 1 (1.1%) | .07 |
| History of HSCT ≥100 d | 3 (17.6%) | 9 (10.2%) | .41 |
| Clinical characteristics | |||
| Any viral coinfection | 2 (17.6%) | 8 (9.1%) | .66 |
| Any bacterial coinfectiona | 5 (29.4%) | 5 (5.7%) | .009 |
| Any respiratory support | 17 (100.0%) | 58 (65.9%) | .003 |
| Any cardiovascular involvement | 13 (76.5%) | 22 (25.0%) | <.001 |
| Receipt of vasoactive infusions | 13 (76.5%) | 11 (12.5%) | <.001 |
| Any neurologic involvement | 6 (35.3%) | 9 (10.2%) | .02 |
| Any hematologic involvement | 15 (88.2%) | 59 (67.0%) | .09 |
| Any gastrointestinal involvement | 11 (64.7%) | 54 (61.4%) | 1.00 |
Abbreviations: COVID-19, coronavirus disease 2019; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range.
aPatients with a positive bacterial culture from any site within 72 hours of admission that was then adjudicated by study staff.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
